MENU
IBRX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

ImmunityBio (IBRX) Earnings Date & Reports

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases... Show more

Industry: #Biotechnology
A.I. Advisor
published Earnings

IBRX is expected to report earnings to fall 35.00% to -6 cents per share on March 02

ImmunityBio IBRX Stock Earnings Reports
Q4'26
Est.
$-0.06
Q3'26
Missed
by $0.02
Q2'26
Missed
by $0.14
Q1'26
Missed
by $0.55
Q4'25
Beat
by $0.05
The last earnings report on November 09 showed earnings per share of -10 cents, missing the estimate of -7 cents. With 1.18M shares outstanding, the current market capitalization sits at 9.15B.
A.I.Advisor
Nov 03, 2026

ImmunityBio (IBRX) Earnings Preview: Can ANKTIVA Keep Its Record Growth Streak Going?

Key Takeaways

  • ImmunityBio is expected to report third-quarter 2026 results around November 5, 2026, with consensus pointing to a loss of about $0.08 per share on roughly $58.1 million in revenue.
  • The report follows eight consecutive quarters of sequential growth in net product revenue for ANKTIVA, its sole marketed drug, which reached a record $50.7 million in Q2 2026.
  • Investors will be watching whether commercial demand can keep pace with the consensus top line and whether management updates its outlook on label-expansion milestones.
  • A key regulatory catalyst sits just ahead: the FDA's January 6, 2027 decision on the company's application to expand ANKTIVA's bladder-cancer label.
  • You can get more information about the ticker's Major News, Today's Price Move, Price Targets, and Forecast on additional pages, and we invite you to explore them.
  • Explore Trending AI Robots to discover AI-driven trading strategies built for changing market conditions.

Earnings Context and Why It Matters

ImmunityBio, Inc. (IBRX) is a commercial-stage biotechnology company built around ANKTIVA, an immunotherapy that activates the immune system to fight cancer and infectious diseases. Its quarterly earnings have become a direct read on how quickly ANKTIVA is being adopted by urologists, since the drug accounts for nearly all reported revenue. The company has delivered eight straight quarters of sequential product-revenue growth, a rare trajectory for a newly launched oncology therapy. With revenue rising sharply while losses remain substantial, each report tests whether commercial momentum can eventually close the gap toward profitability. For investors, the Q3 2026 print also matters because it arrives just ahead of a pivotal regulatory decision that could meaningfully expand the drug's addressable market.

Earnings Expectations

Analysts expect ImmunityBio to report a loss of roughly $0.08 per share on revenue of about $58.1 million for the third quarter of 2026, according to consensus estimates. That compares with adjusted losses of $0.08 per share and total revenue of $51.2 million reported in Q2 2026, when net product revenue from ANKTIVA climbed 92% year over year to a record $50.7 million.

Investors should note the distinction between GAAP and non-GAAP results. In Q2 2026, the company's GAAP net loss attributable to common stockholders was $230.4 million, or $0.22 per share, inflated by non-cash changes in the fair value of a related-party convertible note and warrant liabilities tied to the rising stock price. Management's adjusted (non-GAAP) loss, which strips out those items, was $81.0 million. Beyond the headline figures, the market will focus on net product revenue growth, gross-to-net pricing dynamics, operating expense trends, and the company's cash position, which stood at $357.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking momentum names like IBRX, it offers a practical way to surface comparable setups across the biotech and broader healthcare landscape.

Market Reaction and Investor Sentiment

Sentiment heading into the Q3 2026 report remains optimistic but selective. ImmunityBio shares have surged strongly year to date, buoyed by accelerating ANKTIVA adoption and a string of international regulatory wins, including marketing authorizations in the United Arab Emirates and a broader footprint now spanning roughly 34 countries. At the same time, the stock's rapid appreciation has amplified non-cash fair-value swings on the company's convertible-note and warrant liabilities, which can muddy the reported GAAP bottom line. Investors have tended to reward consistent revenue beats and clear progress on label expansion while reacting cautiously to any sign of slowing sequential growth. The upcoming print will test whether the stock's elevated expectations are justified by continued double-digit sequential gains in product revenue.

Forward Outlook and Key Factors to Monitor

The most important near-term catalyst is regulatory. The U.S. Food and Drug Administration (FDA) is reviewing a supplemental Biologics License Application (sBLA) for ANKTIVA plus BCG in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary disease without carcinoma in situ (CIS). A decision is expected by January 6, 2027, a timeline known as the PDUFA date. BCG refers to Bacillus Calmette-Guérin, the standard immunotherapy used for this type of bladder cancer.

Management has also signaled plans to file for an additional label expansion in BCG-naïve patients, which would represent a much larger opportunity. Investors should monitor any updates on that filing timeline during the earnings call.

On the commercial side, watch the trajectory of net product revenue and any commentary on pricing, reimbursement, and international launches, including the rollout in Saudi Arabia and Europe. Operating costs are also in focus: research and development (R&D) and selling, general, and administrative (SG&A) expenses have been climbing alongside the commercial buildout.

Finally, balance-sheet health remains a watch item. The company carries significant liabilities, including a related-party convertible note and a revenue-interest liability, and continues to burn cash. How management addresses future funding needs will be a key topic for investors looking beyond a single quarter's revenue print.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations